SOD1–G93A mice treated with ceftriaxone, a drug that increases EAAT2 protein expression before ALS onset, produced decreased motor neuron loss after two weeks’ treatment, but the effects disappeared in a phase 3 clinical trial [68,69]. The gene discussed is SLC1A2; the disease is amyotrophic lateral sclerosis.